Al­ler­gan caps a bad day with news the FDA has kicked back a sup­ple­men­tal ap­pli­ca­tion for cariprazine

Al­ler­gan $AGN is not hav­ing a good day to­day.

Af­ter post­ing some mixed, weak ex­tend­ed year-two da­ta on its NASH drug, the com­pa­ny end­ed the day with a short note that the FDA had is­sued a refuse-to-file let­ter on its sup­ple­men­tal ap­pli­ca­tion for cariprazine as a new ther­a­py for neg­a­tive symp­toms as­so­ci­at­ed with schiz­o­phre­nia.

The drug was al­ready ap­proved for schiz­o­phre­nia and the acute treat­ment of adult pa­tients with man­ic or mixed episodes as­so­ci­at­ed with bipo­lar I dis­or­der. Ac­cord­ing to Al­ler­gan, the FDA told them that their ap­pli­ca­tion “was not suf­fi­cient­ly com­plete to per­mit a sub­stan­tive re­view.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER